Precision BioSciences, Inc. (DTIL)
DTIL Stock Price Chart
Explore Precision BioSciences, Inc. interactive price chart. Choose custom timeframes to analyze DTIL price movements and trends.
DTIL Company Profile
Discover essential business fundamentals and corporate details for Precision BioSciences, Inc. (DTIL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Mar 2019
Employees
108.00
CEO
Juli Blanche
Description
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
DTIL Financial Timeline
Browse a chronological timeline of Precision BioSciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.71, while revenue estimate is $1.40m.
Earnings released on 5 May 2026
EPS came in at -$0.75 falling short of the estimated -$0.27 by -177.78%, while revenue for the quarter reached $10.84m , beating expectations by +167.60%.
Earnings released on 12 Mar 2026
EPS came in at $0.36 surpassing the estimated -$0.21 by +271.43%, while revenue for the quarter reached $34.20m , beating expectations by +276.90%.
Earnings released on 3 Nov 2025
EPS came in at -$1.84 falling short of the estimated -$0.31 by -493.55%, while revenue for the quarter reached $13.00k , missing expectations by -99.86%.
Earnings released on 7 Aug 2025
EPS came in at -$2.13 falling short of the estimated -$0.09 by -2.27k%, while revenue for the quarter reached $18.00k , missing expectations by -99.67%.
Earnings released on 15 May 2025
EPS came in at -$2.21 falling short of the estimated -$0.43 by -413.95%, while revenue for the quarter reached $29.00k , missing expectations by -99.54%.
Earnings released on 26 Mar 2025
EPS came in at -$3.20 falling short of the estimated -$2.09 by -53.11%, while revenue for the quarter reached $638.00k , missing expectations by -93.62%.
Earnings released on 4 Nov 2024
EPS came in at -$2.83 falling short of the estimated -$0.79 by -258.23%, while revenue for the quarter reached $576.00k , missing expectations by -86.53%.
Earnings released on 1 Aug 2024
EPS came in at $3.46 surpassing the estimated -$0.77 by +549.35%, while revenue for the quarter reached $49.90m , beating expectations by +496.87%.
Earnings released on 13 May 2024
EPS came in at -$0.35 surpassing the estimated -$0.45 by +22.22%, while revenue for the quarter reached $17.58m , beating expectations by +192.09%.
Earnings released on 27 Mar 2024
EPS came in at -$3.35 falling short of the estimated $3.00 by -211.67%, while revenue for the quarter reached $7.04m , missing expectations by -43.61%.
Stock split effective on 14 Feb 2024
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Nov 2023
EPS came in at -$3.00 surpassing the estimated -$5.71 by +47.46%, while revenue for the quarter reached $13.12m , beating expectations by +5.13%.
Earnings released on 4 Aug 2023
EPS came in at -$3.00 surpassing the estimated -$6.91 by +56.58%, while revenue for the quarter reached $19.79m , beating expectations by +210.17%.
Earnings released on 9 May 2023
EPS came in at -$6.91 falling short of the estimated -$6.61 by -4.54%, while revenue for the quarter reached $8.78m , beating expectations by +54.85%.
Earnings released on 9 Mar 2023
EPS came in at -$7.81 falling short of the estimated -$7.21 by -8.32%, while revenue for the quarter reached $10.60m , beating expectations by +55.62%.
Earnings released on 8 Nov 2022
EPS came in at -$6.61 surpassing the estimated -$10.51 by +37.11%, while revenue for the quarter reached $7.36m , missing expectations by -25.31%.
Earnings released on 8 Aug 2022
EPS came in at -$13.21 falling short of the estimated -$12.91 by -2.32%, while revenue for the quarter reached $3.82m , missing expectations by -23.18%.
Earnings released on 9 May 2022
EPS came in at -$13.81 surpassing the estimated -$17.42 by +20.72%, while revenue for the quarter reached $3.32m , missing expectations by -57.11%.
Earnings released on 15 Mar 2022
EPS came in at -$11.41 surpassing the estimated -$14.41 by +20.82%, while revenue for the quarter reached $6.34m , missing expectations by -29.87%.
Earnings released on 10 Nov 2021
EPS came in at -$5.71 surpassing the estimated -$18.02 by +68.31%, while revenue for the quarter reached $24.04m , missing expectations by -70.66%.
Earnings released on 12 Aug 2021
EPS came in at $10.81 surpassing the estimated -$11.41 by +194.74%, while revenue for the quarter reached $68.81m , meeting expectations.
DTIL Stock Performance
Access detailed DTIL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
